Drug intelligence / Profile preview

GDT3nn

Development stage: Preclinical
Lead developer: Century Therapeutics
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies

Overview

GDT3nn is a preclinical-stage investigational immunotherapy developed by Clade Therapeutics, leveraging the gamma/delta (g/d) T-cell receptor (TCR) discovery engine and cell enhancement suite acquired from Gadeta B.V. This cell therapy is designed as an engineerable, off-the-shelf, and scalable stem cell-based medicine with "Universal Targeting" capabilities, primarily aimed at treating solid tumors. Its mechanism involves harnessing g/d T-cells for cancer immunotherapy.

Targets

γδ TCR (T-cell receptor)

Beyond the preview

Go deeper on GDT3nn.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GDT3nn.

Explore the full profile